These results suggest that CA alleviated RH-induced cardiac inflammation and myocardial hypertrophy by reducing the expression of MMP9/COX2/TNF α/IL-17, and that the therapeutic mechanism of 10 mg/kg of BENA did not depend on them. The gene discussed is IL17A; the disease is inflammation.